Search / Trial NCT06227702

Vexus-guided Fluid Management in Patients With Septic Shock After the Resuscitation Phase

Launched by FEDERAL UNIVERSITY OF SÃO PAULO · Jan 18, 2024

Trial Information

Current as of December 21, 2024

Not yet recruiting

Keywords

Vexus Fluid Management Deresuscitation Deaccumulation

ClinConnect Summary

All patients hospitalized or admitted to the intensive care unit with septic shock will be screened for eligibility. Patients will be randomized using an electronic system (RedCap) to receive or not the intervention.

After 24 hours of shock onset, patients without hypoperfusion after informed consent will be allocated into two groups. In intervention arm wil be assessed by VeXus. Patients without signs of venous congestion (VeXus = 0) will continue to be observed every 6 hours. In patients with VeXus ≥1, continuous infusion of intravenous furosemide will be initiated. During the first 48 h...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age over 18 years old.
  • Hospitalization in ICU for at least 48 hours.
  • Patient in septic shock for at least 24 hours and clinically stable defined by mean arterial pressure ≥ 65 mmHg and maximum infusion of 0.20 μg/kg/min of norepinephrine and lactate \< 4.0 mmol/L.
  • Signed informed consent
  • Exclusion Criteria:
  • Patients in use of more than one vasopressor
  • Known right ventricle dysfunction
  • Indication to use furosemide for other reasons
  • Hypernatremia (Na \>160 mmol/L)
  • Advanced acute kidney injury(KDIGO 3)
  • Current renal replacement therapy
  • Anuria for ≥ 6 hours
  • Hepatorenal syndrome
  • Patients in palliative care
  • Furosemide allergy.
  • Rhabdomyolysis.
  • Major burn

Trial Officials

Flavia Machado

Principal Investigator

Federal University of São Paulo

About Federal University Of São Paulo

The Federal University of São Paulo (Universidade Federal de São Paulo - UNIFESP) is a prestigious institution dedicated to advancing education, research, and healthcare in Brazil. Renowned for its commitment to innovation and excellence, UNIFESP plays a pivotal role in clinical research, focusing on a multidisciplinary approach to improve health outcomes. The university fosters collaboration among researchers, healthcare professionals, and community stakeholders, ensuring that clinical trials conducted under its auspices adhere to rigorous ethical standards and contribute valuable insights to the medical field. With a rich history of academic achievement and a strong emphasis on translational research, UNIFESP is a key player in the development of new therapies and medical interventions.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0